scholarly journals Clinical guide to border moulding and secondary impression in complete dentures

2021 ◽  
Vol 7 (4) ◽  
pp. 231-237
Author(s):  
Ashok K ◽  
Suneetha Rao ◽  
M U Swetha ◽  
Prerana Eshwar ◽  
Jyothi S ◽  
...  
Keyword(s):  
Clinical Result ◽  
Clinical Results ◽  
Pivotal Role ◽  
Complete Dentures ◽  
Insight Into ◽  
Denture Treatment

One of the major reason for a successful denture treatment is a good impression and the cast made out of it. It’s a well known fact, that the denture can only be as good as the impressions made. Therefore, attention to every detail and depth of the impressions plays a pivotal role for a successful clinical result, for which border moulding is an essential procedure for the same. Impressions convey operator’s extent of knowledge, understanding and the clinical results that can follow. A combination of a sound knowledge, along with acquired skill, experience, and patience can result in a successful and aesthetic prosthesis with adequate retention, stability and support with minimal post placement corrections. This article gives an insight into the necessary requisites to be followed during border moulding and secondary impression in making of a successful complete dentures.

scholarly journals Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main proteases: potential from a molecular perspective

2021 ◽  
Vol 7 (1) ◽  
pp. FSO640
Author(s):  
Opeyemi S Soremekun ◽  
Kehinde F Omolabi ◽  
Adeniyi T Adewumi ◽  
Mahmoud ES Soliman
Keyword(s):  
Computational Algorithm ◽  
Clinical Results ◽  
Therapeutic Activity ◽  
Binding Mechanism ◽  
Insight Into

Aim: As coronavirus (CoV) disease 2019-associated pneumonia spreads globally, there has been an urgent need to combat the spread and develop vaccines. Materials & methods: We used an integrated computational algorithm to explore the binding mechanism of TMC-310911/ritonavir (RVT) with SARS-CoV-2 and SARS-CoV main proteases. Results: RVT and TMC-310911 had favorable interactions with the proteases, and these high interactions are facilitated by some significant residues such as Asn133, Gly195 and Gln192. Our study further implicated two important rings in the structure of RVT as a possible chemical culprit in its therapeutic activity. Conclusion: Although there are conflicting clinical results on the therapeutic potency of RVT in the treatment of coronavirus disease 2019, our findings provided molecular insight into the binding mechanism of TMC-310911 and RVT with SARS-CoV-2 and SARS-CoV main proteases.

scholarly journals Glenoid Bone Loss Is a Risk Factor for Poor Clinical Results After Coracoid Transfer in Rugby Players With Shoulder Dislocations

2021 ◽  
Vol 9 (3) ◽  
pp. 232596712199323
Author(s):  
Kenta Shibuya ◽  
Takayuki Kawasaki ◽  
Yoshinori Hasegawa ◽  
Yoshinori Gonda ◽  
Yoshiaki Itoigawa ◽  
...  
Keyword(s):  
Clinical Result ◽  
Multiple Logistic Regression Analysis ◽  
Clinical Results ◽  
Complication Rates ◽  
Shoulder Stabilization ◽  
Coracoid Transfer ◽  
Factors Affecting ◽  
Rugby Players ◽  
Poor Clinical Result

Background: Although surgical shoulder stabilization via coracoid transfer in collision athletes is effective and has a low reinjury rate, the factors affecting poor clinical results and the superiority of the 2 stabilization procedures (Bristow and Latarjet) remain unclear. Purpose: To explore the factor(s) affecting poor clinical results of coracoid transfer in a large cohort of rugby players and to compare postoperative function between the Bristow and Latarjet procedures. Study Design: Cohort study; Level of evidence, 3. Methods: This study included 169 consecutive shoulders of 154 competitive male rugby players who underwent shoulder stabilization surgery (Bankart repair with coracoid transfer) between 2014 and 2018 and had a mean follow-up of 2.7 years (minimum follow-up, 2 years). The Bristow procedure was performed in the first 92 shoulders (84 players), and the Latarjet procedure was performed in the latter 77 shoulders (70 players). A poor clinical result was defined as a postoperative Rowe score of <70 and a postoperative Western Ontario Shoulder Instability Index (WOSI) score of >630. Multiple logistic regression analysis was conducted to identify the factors affecting postoperative functional failure. The postoperative scores and complication rates were also compared between the 2 procedures. Results: In total, 92.3% of the rugby players returned to their preinjury competition level at a mean of 5.9 months postoperatively. The Rowe and WOSI scores showed that shoulder function was improved postoperatively compared with preoperatively. The number of rugby players with a poor clinical result was 18 (10.7%). Multiple logistic regression analysis demonstrated that a poor clinical result was associated with a preoperative glenoid bone defect of >20% of the glenoid width (odds ratio, 9.8), whereas the clinical result was unaffected by the type of coracoid transfer. There were no differences between the 2 procedures in any of the postoperative scores or complication rates. Conclusion: The present study indicated that the most effective predictor of postoperative functional scores was the degree of the glenoid bone defect and not the type of coracoid transfer. This information may be useful for the strategic treatment of shoulder dislocations in collision athletes.

scholarly journals An improved structural model of the human iron exporter ferroportin. Insight into the role of pathogenic mutations in hereditary hemochromatosis type 4

2017 ◽  
Vol 13 (4) ◽  
Author(s):  
Valentina Tortosa ◽  
Maria Carmela Bonaccorsi di Patti ◽  
Valentina Brandi ◽  
Giovanni Musci ◽  
Fabio Polticelli
Keyword(s):  
Membrane Protein ◽  
Crystal Structures ◽  
Iron Homeostasis ◽  
Structural Model ◽  
Hereditary Hemochromatosis ◽  
Structural Models ◽  
Pivotal Role ◽  
Cellular Iron ◽  
Insight Into

AbstractFerroportin (Fpn) is a membrane protein representing the major cellular iron exporter, essential for metal translocation from cells into plasma. Despite its pivotal role in human iron homeostasis, many questions on Fpn structure and biology remain unanswered. In this work, we present two novel and more reliable structural models of human Fpn (hFpn; inward-facing and outward-facing conformations) obtained using as templates the recently solved crystal structures of a bacterial homologue of hFpn,

scholarly journals Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy

2020 ◽  
Author(s):  
Dimitrios C. Mastellos ◽  
Bruno G. P. Pires da Silva ◽  
Benedito A. L. Fonseca ◽  
Natasha P. Fonseca ◽  
Maria A. Martins ◽  
...  
Keyword(s):  
Clinical Evidence ◽  
Clinical Results ◽  
Clinical Findings ◽  
Complement C3 ◽  
Drug Candidate ◽  
Steep Decline ◽  
Prospective Trials ◽  
Mechanistic Basis ◽  
Terminal Complement ◽  
Insight Into

Growing clinical evidence has implicated complement as a pivotal driver of COVID-19 immunopathology. Deregulated complement activation may fuel thrombotic microangiopathy and NET-driven immunothrombosis, thereby exacerbating cytokine-driven hyper-inflammation and multi-organ failure. Complement therapeutics have gained traction as candidate drugs for countering the detrimental consequences of SARS-CoV-2 infection. Whether blockade of terminal complement effectors (C5, C5a, or C5aR1) can elicit similar outcomes to upstream intervention at the level of C3 remains debated. Here we have compared the clinical efficacy of the C5-targeting mAb eculizumab with that of the compstatin-based C3-targeted drug candidate AMY-101 in small independent cohorts of severe, mainly non-intubated COVID-19 patients. Our exploratory study indicates that therapeutic complement inhibition abrogates COVID-19 hyper-inflammation. Both C3 and C5 inhibitors elicit a robust anti-inflammatory response, reflected by a steep decline in CRP and IL-6 levels, associated with marked lung function improvement and resolution of SARS-CoV-2-associated ARDS. C3 inhibition afforded broader therapeutic control in COVID19 patients by attenuating both C3a and sC5b-9 generation and preventing FB consumption. This broader inhibitory profile of anti-C3 treatment was associated with a more robust decline of neutrophil counts, a greater decline of median LDH levels and more prominent lymphocyte recovery within the first 7 days of treatment. These early clinical results offer important insight into the differential mechanistic basis and underlying biology of C3 and C5 inhibition in COVID-19. They point to a broader pathogenic involvement of C3-mediated pathways and set the stage for larger prospective trials that will benchmark these complement-targeting agents in COVID-19.

In Search of Guidance

2020 ◽  
pp. 37-60
Author(s):  
Robert Collis ◽  
Natalie Bayer
Keyword(s):  
Pivotal Role ◽  
Large Measure ◽  
Depth Study ◽  
Insight Into

This chapter examines the eleven-month residence of Tadeusz Grabianka in London, between December 1785 and November 1786. It undertakes an in-depth study of the extraordinary series of twelve meetings that took place during this time between Grabianka and Samuel Best, known as the so-called Shoreditch Prophet and Poor-Help. These encounters were noted down by Grabianka and provide a fascinating insight into both his and Best’s prophetic and millenarian mindsets. It also reveals the wider prevalence of millenarianism in London and beyond at the time and, moreover, illustrates Best’s pivotal role in fomenting this sentiment. The chapter also analyses the close ties between Grabianka, Best, and the burgeoning Swedenborgian milieu in the English capital in the 1780s. In large measure, these links were facilitated by Benedict Chastanier and William Bousie, who rank as two of the foremost Anglo-French illuminists of the era, and who both went on to join the Avignon Society in the late 1780s.

scholarly journals Role of Nanomedicine in Management and Prevention of COVID-19

2020 ◽  
Vol 2 ◽  
Author(s):  
Jitendra N. Wankar ◽  
Vivek K. Chaturvedi ◽  
Chandrashekhar Bohara ◽  
Mohan P. Singh ◽  
Raghvendra A. Bohara
Keyword(s):  
Side Effects ◽  
Severe Acute Respiratory Syndrome ◽  
Disease Outbreak ◽  
Target Site ◽  
Inorganic Materials ◽  
Pivotal Role ◽  
The World ◽  
Insight Into

COVID-19, or the Coronavirus disease 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic. At the time of writing this (July 28, 2020), more than 17 million people have become affected and 0.7 million people have died across the world. Remdesivir has shown glimpses of insight into how to fight the virus, but as of yet remain far from victory. Nanotechnology has proven its role in medicine to deliver the drug at the target site with minimal side effects, particularly in the anticancer domain. Most specifically, a range of nanotechnology-based products, such as nanosilver, are currently on the market because they have demonstrated the potential to combat viruses. This article provides an overview of the role of nanomedicine, including polymeric and inorganic materials, and its future capabilities in the management of the disease outbreak. Taking all this into account, an attempt has been made to educate readers in the simplest way of the role of nanomedicine, which can play a pivotal role in the management of diseases.

scholarly journals Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy

Cells ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 1485 ◽  
Author(s):  
Jan A. Rath ◽  
Caroline Arber
Keyword(s):  
T Cell ◽  
Cell Receptor ◽  
Clinical Results ◽  
Adoptive T Cell Therapy ◽  
Great Promise ◽  
T Cell Therapy ◽  
Cell Therapies ◽  
Challenges And Opportunities ◽  
The Impact ◽  
Insight Into

T cell receptor (TCR)-based adoptive T cell therapies (ACT) hold great promise for the treatment of cancer, as TCRs can cover a broad range of target antigens. Here we summarize basic, translational and clinical results that provide insight into the challenges and opportunities of TCR-based ACT. We review the characteristics of target antigens and conventional αβ-TCRs, and provide a summary of published clinical trials with TCR-transgenic T cell therapies. We discuss how synthetic biology and innovative engineering strategies are poised to provide solutions for overcoming current limitations, that include functional avidity, MHC restriction, and most importantly, the tumor microenvironment. We also highlight the impact of precision genome editing on the next iteration of TCR-transgenic T cell therapies, and the discovery of novel immune engineering targets. We are convinced that some of these innovations will enable the field to move TCR gene therapy to the next level.

scholarly journals Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application

Cancers ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 915 ◽  
Author(s):  
Mulder ◽  
Wahlin ◽  
Österborg ◽  
Palma
Keyword(s):  
B Cell ◽  
Immune Cells ◽  
Clinical Results ◽  
Lymphocytic Leukemia ◽  
Inflammatory Microenvironment ◽  
Different Types ◽  
Survival And Growth ◽  
Characteristic Features ◽  
Insight Into

In lymphomas of B-cell origin, cancer cells orchestrate an inflammatory microenvironment of immune and stromal cells that sustain the tumor cell survival and growth, known as a tumor microenvironment (TME). The features of the TME differ between the different lymphoma types, ranging from extremely inflammatory, such as in Hodgkin lymphoma, to anergic, leading to immune deficiency and susceptibility to infections, such as in chronic lymphocytic leukemia. Understanding the characteristic features of the TME as well as the interactions between cancer and TME cells has given insight into the pathogenesis of most lymphomas and contributed to identify novel therapeutic targets. Here, we summarize the preclinical data that contributed to clarifying the role of the immune cells in the TME of different types of lymphomas of B-cell origin, and explain how the understanding of the biological background has led to new clinical applications. Moreover, we provide an overview of the clinical results of trials that assessed the safety and efficacy of drugs directly targeting TME immune cells in lymphoma patients.

Sign in / Sign up

Export Citation Format

Share Document